GLP-1 Treatments
Updated April 2026

Oral Semaglutide
(Rybelsus) in the UK

Everything UK patients need to know about the tablet form of semaglutide: availability, cost, how it compares with injectable Ozempic, clinical evidence and who it is suitable for.

Key facts

  • Brand name: Rybelsus (Novo Nordisk)
  • Active ingredient: Semaglutide — the same molecule as Ozempic and Wegovy
  • UK licence: Approved for type 2 diabetes; not yet licensed for weight management at current doses
  • Available doses: 3 mg (starter), 7 mg (maintenance), 14 mg (maximum licensed dose)
  • How it works: Same GLP-1 receptor agonist mechanism — reduces appetite, slows gastric emptying, improves glycaemic control
  • Administration: One tablet daily, on an empty stomach, with up to 120 ml of plain water, then wait 30 minutes before eating

What is oral semaglutide?

Oral semaglutide is the first GLP-1 receptor agonist available in tablet form. Until its development, all GLP-1 RAs required subcutaneous injection because peptide molecules are normally destroyed by stomach acid and digestive enzymes. Novo Nordisk overcame this barrier by co-formulating semaglutide with an absorption enhancer called sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, or SNAC. This compound temporarily raises the local pH in the stomach and facilitates semaglutide absorption through the gastric lining.

The result is a tablet that delivers semaglutide into the bloodstream, albeit with a bioavailability of only about 0.4 to 1 per cent. This low absorption rate is why the oral doses (measured in milligrams) are much higher than the injectable doses (measured in micrograms or low milligrams), and why strict dosing conditions are essential.

UK availability and licensing

Rybelsus received MHRA approval and has been available in the UK since 2020 for the treatment of type 2 diabetes in adults. It is positioned as an option when metformin alone, or metformin combined with other oral agents, has not achieved adequate blood sugar control.

NHS availability

NICE has appraised oral semaglutide for type 2 diabetes. It is available on the NHS as part of the diabetes treatment pathway, typically considered after metformin and one or two other agents. Your diabetes specialist or GP can prescribe it if you meet the clinical criteria.

Rybelsus is not currently available on the NHS for weight management. The NHS weight management pathway uses injectable semaglutide (Wegovy) at the 2.4 mg weekly dose, which is a different product and dosing regimen.

Private availability

Some private clinics and online prescribers offer Rybelsus off-label for weight management. However, at the currently licensed maximum dose of 14 mg daily, the weight loss achieved is generally less than that seen with injectable semaglutide at 2.4 mg weekly. Patients considering this route should discuss the cost-effectiveness and expected outcomes with their prescriber.

Higher doses on the horizon: Novo Nordisk has been developing oral semaglutide at doses of 25 mg and 50 mg daily specifically for weight management. These higher doses, tested in the OASIS trials, show weight loss results much closer to injectable semaglutide. A UK marketing authorisation for these doses has not yet been granted as of April 2026.

How oral semaglutide compares with injectable Ozempic

Both Rybelsus and Ozempic contain the same active ingredient, semaglutide. However, there are important practical differences:

Feature Rybelsus (oral) Ozempic (injection)
Route Oral tablet, daily Subcutaneous injection, once weekly
Licensed indication (UK) Type 2 diabetes Type 2 diabetes
Doses 3 mg, 7 mg, 14 mg daily 0.25 mg, 0.5 mg, 1 mg, 2 mg weekly
HbA1c reduction Approximately 1.0–1.4% (14 mg) Approximately 1.5–1.8% (1 mg)
Weight loss (diabetes trials) Approximately 3–5 kg (14 mg) Approximately 4–6 kg (1 mg)
Dosing conditions Empty stomach, plain water only, 30-min fast Any time, regardless of meals
Needle required No Yes (pre-filled pen)
Approximate private cost/month £150–£250 £150–£300

Key takeaway: Injectable semaglutide generally achieves greater HbA1c reduction and weight loss than oral semaglutide at currently licensed doses. The oral form is best suited to patients who strongly prefer not to inject and accept a slightly lower efficacy, or who are using it as part of a diabetes treatment regimen where the convenience of a tablet matters.

Clinical evidence: PIONEER and OASIS trials

The PIONEER programme

The PIONEER programme comprised ten phase 3 clinical trials evaluating oral semaglutide at doses up to 14 mg daily, primarily in patients with type 2 diabetes. Key findings included:

Across the programme, the side-effect profile was consistent with injectable GLP-1 RAs: the most common adverse events were gastrointestinal (nausea, diarrhoea, vomiting), typically mild to moderate and most frequent during dose escalation.

The OASIS trials: higher doses for weight management

Recognising that the 14 mg dose was insufficient for meaningful weight loss in obesity, Novo Nordisk developed higher oral semaglutide doses (25 mg and 50 mg daily) and tested them in dedicated weight management trials:

These results suggest that, at sufficiently high doses, oral semaglutide can match the efficacy of injectable formulations. However, the 25 mg and 50 mg doses are not yet licensed in the UK and their availability depends on regulatory review and NICE appraisal.

How to take oral semaglutide correctly

The strict dosing regimen is critical to absorption. Deviating from these conditions can dramatically reduce the amount of semaglutide that enters your bloodstream:

  1. Take it first thing in the morning on a completely empty stomach (at least 6 hours since your last food or drink)
  2. Swallow the tablet whole with up to half a glass (approximately 120 ml) of plain water only — not with tea, coffee, juice or sparkling water
  3. Do not crush, chew or split the tablet, as this damages the SNAC formulation
  4. Wait at least 30 minutes before eating breakfast, drinking anything else, or taking other oral medications
  5. Start at 3 mg daily for at least 4 weeks, then increase to 7 mg. After at least 4 weeks on 7 mg, your prescriber may increase to 14 mg if needed

Common mistake: Taking Rybelsus with food, coffee, or more than 120 ml of water can reduce absorption by up to 40 per cent or more, significantly reducing efficacy. If you struggle with the fasting requirement, discuss whether injectable semaglutide might be more practical for you.

Who is oral semaglutide suitable for?

Oral semaglutide may be particularly appropriate for:

It may be less suitable for:

Side effects

The side-effect profile of oral semaglutide is similar to injectable GLP-1 RAs. The most common adverse effects are gastrointestinal:

For a full breakdown, see our GLP-1 side effects guide and Ozempic side effects (UK) page. The same contraindications apply as with injectable semaglutide, including a personal or family history of medullary thyroid carcinoma or MEN2.

Cost in the UK

NHS

When prescribed on the NHS for type 2 diabetes, patients pay the standard prescription charge (£9.90 per item in England as of 2026, free in Scotland, Wales and Northern Ireland). The NHS list price for Rybelsus is approximately £65–£75 for 30 tablets depending on the dose, though NHS procurement costs may differ.

Private prescription

Private costs for Rybelsus typically range from approximately £150 to £250 per month depending on the dose and pharmacy. Some weight loss clinics include consultation fees on top. When comparing cost-effectiveness, consider that injectable semaglutide may achieve greater weight loss per pound spent, particularly if weight management is the primary goal.

Frequently asked questions

Is oral semaglutide (Rybelsus) available in the UK?

Yes. Rybelsus is MHRA-approved and available in the UK for type 2 diabetes. It can be prescribed on the NHS as part of the diabetes treatment pathway. It is not yet licensed for weight management at current doses, though some private clinics offer it off-label.

How does oral semaglutide compare to injectable Ozempic?

Both contain semaglutide and share the same mechanism. Injectable Ozempic (once weekly) generally produces greater HbA1c reduction and weight loss than oral semaglutide at currently licensed doses. The oral form requires daily dosing on an empty stomach, while Ozempic is a once-weekly injection taken at any time.

How much does Rybelsus cost privately in the UK?

Private prescription costs typically range from approximately £150 to £250 per month depending on dose and pharmacy. This can be more expensive than injectable semaglutide on a cost-per-efficacy basis.

What were the PIONEER and OASIS trials?

PIONEER was a series of ten phase 3 trials evaluating oral semaglutide (up to 14 mg daily) for type 2 diabetes. OASIS 1 and OASIS 2 tested higher doses (25 mg and 50 mg daily) specifically for weight management, showing weight loss of approximately 15 to 17 per cent — comparable to injectable semaglutide at 2.4 mg weekly.

Do I have to take oral semaglutide on an empty stomach?

Yes. Take it first thing in the morning with up to 120 ml of plain water. Wait at least 30 minutes before eating, drinking anything else, or taking other oral medications. This is essential for the SNAC absorption enhancer to work effectively.

Related guides

Sources